Characterization of the neutralizing activity of digoxin-specific fab toward ouabain-like steroids

被引:43
作者
Pullen, MA [1 ]
Brooks, DP [1 ]
Edwards, RM [1 ]
机构
[1] GlaxoSmithKline Pharmaceut, Dept Renal Biol, King Of Prussia, PA USA
关键词
D O I
10.1124/jpet.104.065250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Digoxin-specific Fab ( Digibind) is a mixture of antidigoxin Fab fragments prepared from sheep sera and is used as a treatment for digoxin poisoning. Digoxin-specific Fab has been shown to neutralize an endogenous Na+/K+ ATPase inhibitor ( endogenous digoxin-like Na+/K+ ATPase regulatory factor; EDLF) in rats and humans and to lower blood pressure. Although the exact structure of EDLF is unknown, compounds identical to or structurally related to ouabain, bufalin, and marinobufagenin have been detected in mammalian plasma. In this study, some structural characteristics of EDLF were inferred from the ability of digoxin-specific Fab to neutralize the Na+/K+ ATPase inhibitory activity of several known cardenolides and bufodienolides. Additional structural information was obtained from [H-3]ouabain binding and enzyme-linked immunosorbent assay experiments. Digoxin-specific Fab had the ability to interact to some extent with all of the cardenolides and bufodienolides tested. However, digoxin-specific Fab was more than 20-fold more potent in neutralizing ouabain and bufalin than marinobufagenin. The antihypertensive effect of digoxin-specific Fab seen in preeclampsia and animal models of hypertension may therefore be due to a molecule identical to or structurally similar to ouabain or bufalin.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 40 条
[1]  
Adair CD, 1996, AM J NEPHROL, V16, P529
[2]   Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+,K+-pump in human mesenteric arteries [J].
Bagrov, AY ;
Fedorova, OV .
JOURNAL OF HYPERTENSION, 1998, 16 (12) :1953-1958
[3]   Characterization of a urinary bufodienolide Na+,K+-ATPase inhibitor in patients after acute myocardial infarction [J].
Bagrov, AY ;
Fedorova, OV ;
Dmitrieva, RI ;
Howald, WN ;
Hunter, AP ;
Kuznetsova, EA ;
Shpen, VM .
HYPERTENSION, 1998, 31 (05) :1097-1103
[4]  
Bagrov AY, 1996, CARDIOVASC RES, V31, P296
[5]  
BALZAN S, 1991, J HYPERTENS, V9, pS304
[6]   Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor [J].
Balzan, S ;
D'Urso, G ;
Ghione, S ;
Martinelli, A ;
Montali, U .
LIFE SCIENCES, 2000, 67 (16) :1921-1928
[7]   Treatment of toad venom poisoning with digoxin-specific Fab fragments [J].
Brubacher, JR ;
Ravikumar, PR ;
Bania, T ;
Heller, MB ;
Hoffman, RS .
CHEST, 1996, 110 (05) :1282-1288
[8]   Efficacy of digoxin specific Fab fragments (Digibind®) in the treatment of toad venom poisoning [J].
Brubacher, JR ;
Lachmanen, D ;
Ravikumar, PR ;
Hoffman, RS .
TOXICON, 1999, 37 (06) :931-942
[9]   ISOLATION OF DIGOXIN-SPECIFIC ANTIBODY AND ITS USE IN REVERSING EFFECTS OF DIGOXIN [J].
CURD, J ;
SMITH, TW ;
JATON, JC ;
HABER, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1971, 68 (10) :2401-&
[10]   Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: Monitoring the effect by measuring free digitoxin concentrations [J].
Dasgupta, A ;
Emerson, L .
LIFE SCIENCES, 1998, 63 (09) :781-788